Actively Recruiting
Study of Optilume Drug-Coated Balloon Device for Treating Ureteric Strictures by Endoscopy
Led by Urotronic Inc. · Updated on 2026-03-09
60
Participants Needed
7
Research Sites
230 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and feasibility of the Optilume drug-coated balloon DCB for treating ureteric strictures, which are narrowings of the ureter. This interventional study focuses on patients with single ureteric or uretero-enteric strictures up to 4.0 cm in length and functioning kidneys. The trial is sponsored by Urotronic Inc. and aims to assess the treatments success approximately 7 months after the procedure. Participants will receive the Optilume device treatment, which involves a pre-treatment step such as balloon dilation or ureterotomy, followed by use of the paclitaxel-coated balloon on the ureteric stricture. This single-arm study does not use masking or blinding. The study starts in October 2025 and continues until July 2031. During the trial, participants will be monitored for successful treatment outcomes at 6 months after ureteral stent removal, which is about 7 months after the Optilume treatment. Follow-up will include assessments of kidney function and imaging when needed. Participants must meet specific eligibility criteria and will be monitored for safety and treatment effectiveness throughout the study period.
CONDITIONS
Brief Title
EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
Research Team
S
Steven M Principal Clinical Project Manager
R
Reem Ennenga
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here